Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Fennec Pharmaceuticals Inc (FENC)

Fennec Pharmaceuticals Inc (FENC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 224,087
  • Shares Outstanding, K 34,475
  • Annual Sales, $ 44,640 K
  • Annual Income, $ -9,740 K
  • EBIT $ -6 M
  • EBITDA $ -6 M
  • 60-Month Beta 0.93
  • Price/Sales 4.83
  • Price/Cash Flow N/A
  • Price/Book 6.02

Options Overview Details

View History
  • Implied Volatility 290.97% (+9.84%)
  • Historical Volatility 86.89%
  • IV Percentile 43%
  • IV Rank 38.24%
  • IV High 674.76% on 03/18/26
  • IV Low 53.33% on 05/20/25
  • Expected Move (DTE 28) 0.00 (0.00%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 2
  • Volume Avg (30-Day) 59
  • Put/Call OI Ratio 0.05
  • Today's Open Interest 1,532
  • Open Int (30-Day) 1,572
  • Expected Range 6.30 to 6.30

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.02
  • Number of Estimates 4
  • High Estimate $0.01
  • Low Estimate $-0.04
  • Prior Year $-0.04
  • Growth Rate Est. (year over year) +50.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.65 +11.50%
on 04/13/26
8.10 -22.22%
on 03/17/26
-1.50 (-19.23%)
since 03/16/26
3-Month
5.65 +11.50%
on 04/13/26
9.19 -31.41%
on 02/18/26
-1.29 (-17.00%)
since 01/16/26
52-Week
5.02 +25.50%
on 04/21/25
9.92 -36.49%
on 10/06/25
+1.20 (+23.53%)
since 04/16/25

Most Recent Stories

More News
Fennec Pharmaceuticals Announces Investigator-Sponsored Study to Be Conducted by University of Arizona Cancer Center

~ University of Arizona Cancer Center Initiating Study to Explore Use of PEDMARK ® in AYA & Adult Patients with Solid Tumors Receiving Cisplatin ~ ~ This New Study and Other Independent, Institution-Led...

FRX.TO : 8.50 (-1.73%)
FENC : 6.30 (-3.08%)
Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

RESEARCH TRIANGLE PARK, N.C., March 31, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced...

FRX.TO : 8.50 (-1.73%)
FENC : 6.30 (-3.08%)
Fennec Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

~ Delivered Record Annual Revenue with Full-Year Net PEDMARK ®  Product Sales of $44.6 Million, Representing 50% Year-Over-Year Growth, and Q4 2025 Net Product Sales of $13.8 Million, Representing...

FRX.TO : 8.50 (-1.73%)
FENC : 6.30 (-3.08%)
Fennec Pharmaceuticals to Report Full Year and Fourth Quarter 2025 Financial Results on March 24, 2026

RESEARCH TRIANGLE PARK, N.C., March 18, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company...

FRX.TO : 8.50 (-1.73%)
FENC : 6.30 (-3.08%)
Fennec Pharmaceuticals Announces Settlement Agreement Resolving PEDMARK Patent Litigation

RESEARCH TRIANGLE PARK, N.C., March 16, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today announces that it has entered into an agreement...

FRX.TO : 8.50 (-1.73%)
FENC : 6.30 (-3.08%)
Fennec Pharmaceuticals Announces Clinical Research Collaboration with Tampa General Hospital Cancer Institute

RESEARCH TRIANGLE PARK, N.C., March 04, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today announced that the Tampa General Hospital...

FRX.TO : 8.50 (-1.73%)
FENC : 6.30 (-3.08%)
Fennec Pharmaceuticals Presents Real World Data Supporting the Integration and Clinical Use of PEDMARK® in Treating Adults with Head & Neck Cancers

– Administration of PEDMARK ® Approximately Six Hours After Cisplatin was Shown to Be Safe & Easily Integrated into Care for Adults with Head & Neck Cancers (HNC) – – Early Signals of...

FRX.TO : 8.50 (-1.73%)
FENC : 6.30 (-3.08%)
Southpoint holdings in Fennec Pharmaceuticals Inc. (TSX: FENC)

NEW YORK, Dec. 26, 2025 (GLOBE NEWSWIRE) -- Southpoint Capital Advisors LP (“Southpoint”), acting on behalf of certain Southpoint funds for which it serves as investment manager, announces that on...

FRX.TO : 8.50 (-1.73%)
FENC : 6.30 (-3.08%)
Fennec Pharmaceuticals Announces Investigator-Sponsored Trial to Be Conducted by City of Hope in Metastatic Testicular Germ Cell Tumors

– City of Hope to Evaluate PEDMARK ® for Reducing Ototoxicity in Adult Men with Stage II-III Metastatic Testicular Germ Cell Tumors – – Initiation of Study Reflects Growing Clinical Interest...

FRX.TO : 8.50 (-1.73%)
FENC : 6.30 (-3.08%)
Fennec Pharmaceuticals Announces Positive Topline Results From Investigator-Initiated Clinical Study of PEDMARK® in Japan to Reduce Cisplatin-Induced Hearing Loss

– Study, Which Enrolled 27 Patients, Met Primary Endpoint with a Significant Reduction in Hearing Loss in 3-18 Year Old Patients who Received PEDMARK ® when Compared with Historically Reported...

FRX.TO : 8.50 (-1.73%)
FENC : 6.30 (-3.08%)

Business Summary

Fennec Pharmaceuticals Inc. is a clinical-stage biotechnology company. It is focused on the development of Sodium Thiosulfate for the prevention of ototoxicity from cisplatin in pediatric patients. The Company's products include Eniluracil and Sodium Thiosulfate (STS). Fennec Pharmaceuticals Inc., formerly...

See More

Key Turning Points

3rd Resistance Point 7.02
2nd Resistance Point 6.79
1st Resistance Point 6.55
Last Price 6.30
1st Support Level 6.08
2nd Support Level 5.85
3rd Support Level 5.61

See More

52-Week High 9.92
Fibonacci 61.8% 8.05
Fibonacci 50% 7.47
Fibonacci 38.2% 6.89
Last Price 6.30
52-Week Low 5.02

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.